Forte Biosciences (FBRX) EPS (Weighted Average and Diluted) (2021 - 2026)
Forte Biosciences (FBRX) reported EPS (Weighted Average and Diluted) of -$1.24 for Q1 2026, up 9.49% year-over-year from -$1.13 in Q1 2025, and up 14.48% quarter-over-quarter from -$1.45 in Q4 2025.
Forte Biosciences (FBRX) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.24 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.24, up 9.49% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.64 (up 51.21% YoY), and the FY2025 annual result was -$4.71, up 61.3% from the prior year.
- EPS (Weighted Average and Diluted) climbed to -$1.24 in Q1 2026 per FBRX's latest filing, from -$1.45 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $3.18 in Q4 2024 and troughed at -$6.78 in Q2 2024.
- A 5-year average of -$1.6 and a median of -$0.96 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) slumped 3550.0% in 2023, then soared 434.74% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.24 in 2022, then sank by 295.83% to -$0.95 in 2023, then soared by 434.74% to $3.18 in 2024, then tumbled by 145.6% to -$1.45 in 2025, then gained by 14.48% to -$1.24 in 2026.
- Business Quant data shows FBRX's EPS (Weighted Average and Diluted) at -$1.24 in Q1 2026, -$1.45 in Q4 2025, and -$0.99 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | -1.24 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.24 |
| Dec 31, 2025 | -1.45 |
| Sep 30, 2025 | -0.99 |
| Jun 30, 2025 | -0.96 |
| Mar 31, 2025 | -1.37 |
| Dec 31, 2024 | 3.18 |
| Sep 30, 2024 | -4.54 |
| Jun 30, 2024 | -6.78 |
| Mar 31, 2024 | -4.03 |
| Dec 31, 2023 | -0.95 |
| Sep 30, 2023 | -6.57 |
| Jun 30, 2023 | -0.42 |
| Mar 31, 2023 | -0.32 |
| Dec 31, 2022 | -0.24 |
| Sep 30, 2022 | -0.18 |
| Jun 30, 2022 | -0.21 |
| Mar 31, 2022 | -0.17 |
| Dec 31, 2021 | -0.21 |
| Sep 30, 2021 | -0.54 |
| Jun 30, 2021 | -0.43 |